Aurobindo Pharma Subsidiary Receives ANVISA Approval for Biosimilars Manufacturing Facility in Hyderabad
Aurobindo Pharma Limited’s wholly owned subsidiary, CuraTeQ Biologics Private Limited, has secured approval from ANVISA (Agência Nacional de Vigilância Sanitária), Brazil's National Health Surveillance Agency. The approval pertains to its biosimilars manufacturing facility located in Hyderabad.The status of the facility was assessed following a rigorous Good Manufacturing Practice GMP inspection conducted by ANVISA between May 11 and May 15, 2026. This endorsement was granted after successful completion of the inspection for biological API and sterile products at the site.
The scope of the comprehensive GMP inspection covered four biosimilar products. The facility features a mammalian and microbial drug substance manufacturing unit, along with dedicated prefillable syringe and vial filling facilities, packaging and labelling capabilities, and in-house QC testing and release laboratories.
The new ANVISA approval reinforces CuraTeQ Biologics' commitment to maintaining high standards of global regulatory compliance and quality. The subsidiary’s GMP facility is already certified by both the EMA (European Medicines Agency) and WHO. This expanded accreditation strengthens Aurobindo Pharma Limited's capabilities, enabling it to supply biosimilar products efficiently across the Brazilian market and broader Latin American regions.
AUROPHARMA Stock Price Movement
Today, shares of Aurobindo Pharma Limited rallied, settling at ₹1579.70 after the stock edged up 1.44%. The equity traded within a tight range for the day, finding support near ₹1547.30 and peaking at ₹1584.80 in trading.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.